SCHEMBL1961432

SCHEMBL1961432

Cc1nc(C(=O)Nc2cc(-c3ccnc(N)c3)cc3[nH]ncc23)cs1

nearest known ligand 0.62

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PIK3CD O00329 10/20 0.62
PIK3CG P48736 7/20 0.62
PIK3CA P42336 7/20 0.62
PIK3CB P42338 6/20 0.62
PIM1 P11309 6/20 0.54
GSK3B P49841 6/20 0.54
TLR7 Q9NYK1 1/20 0.41
IRAK4 Q9NWZ3 2/20 0.39
BACE1 P56817 1/20 0.39
JAK2 O60674 3/20 0.38
JAK1 P23458 3/20 0.38
TYK2 P29597 3/20 0.38
JAK3 P52333 3/20 0.38
PDPK1 O15530 1/20 0.38
MAPK1 P28482 1/20 0.37
MAPT P10636 1/20 0.37
TDP1 Q9NUW8 1/20 0.37
KCNH2 Q12809 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL12274330 0.99 PIK3CD (0.61) PIK3CDPIK3CGPIK3CAPIK3CBPIM1
SCHEMBL459145 0.87 PIK3CD (0.64) PIK3CDPIK3CGPIK3CAPIK3CBPIM1
SCHEMBL470108 0.85 PIK3CD (0.62) PIK3CDPIK3CGPIK3CAPIK3CBPIM1
SCHEMBL1960498 0.85 PIK3CD (0.72) PIK3CDPIK3CGPIK3CAPIK3CBPIM1
SCHEMBL1956941 0.84 PIK3CD (0.71) PIK3CDPIK3CGPIK3CAPIK3CBPIM1
SCHEMBL12522521 0.84 PIK3CD (0.65) PIK3CDPIK3CGPIK3CAPIK3CBPIM1
SCHEMBL458840 0.84 PIK3CD (0.61) PIK3CDPIK3CGPIK3CAPIK3CBPIM1
SCHEMBL459665 0.84 PIK3CD (0.61) PIK3CDPIK3CGPIK3CAPIK3CBPIM1
SCHEMBL1771874 0.84 PIK3CD (0.71) PIK3CDPIK3CGPIK3CAPIK3CBPIM1
SCHEMBL1959680 0.84 PIK3CD (0.62) PIK3CDPIK3CGPIK3CAPIK3CBPIM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2507231-A1 INDAZOLE DERIVATIVES AS PI 3 - KINASE INHIBITORS Glaxo Group Limited (GB) 2012-10-10 EP claimed
WO-2011067366-A1 INDAZOLE DERIVATIVES AS PI 3 - KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 2011-06-09 WO claimed
EP-2507231-A1 INDAZOLE DERIVATIVES AS PI 3 - KINASE INHIBITORS Glaxo Group Limited (GB) 2012-10-10 EP disclosed
US-20120238571-A1 INDAZOLE DERIVATIVES AS PI 3-KINASE GLAXO GROUP LIMITED (GB) 2012-09-20 US disclosed
US-20120238571-A1 INDAZOLE DERIVATIVES AS PI 3-KINASE GLAXO GROUP LIMITED (GB) 2012-09-20 US disclosed
US-20120238571-A1 INDAZOLE DERIVATIVES AS PI 3-KINASE GLAXO GROUP LIMITED (GB) 2012-09-20 US disclosed
WO-2011067366-A1 INDAZOLE DERIVATIVES AS PI 3 - KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 2011-06-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120238571-A1 INDAZOLE DERIVATIVES AS PI 3-KINASE PI4KA, PIP4K2B, PI4KB PIK3CD 11/4885PIK3CG 15/4885PIK3CA 12/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.